Rome, June 3, 2022 - The Shareholders' Meeting of ENAV S.p.A., which met today under the chairmanship of Francesca Isgrò, approved the Company's financial statements for the year 2021 and viewed the 2021 consolidated financial statements for the Group.

Key financial results

• Revenue: € 836.6 million (+8.5% comparated to 2020)
• Record non-regulation market revenues: € 33,0 million (+22.3% comparated to 2020)
• EBITDA: € 222.4 million (+5.5% comparated to 2020)
• EBIT: € 98.3 million  (+38.2% comparated to 2020)
• Net profit: € 78 million (+44.6% comparated to 2020)
• Net financial position: € 483.5 million

Dividend proposal

The Shareholders' Meeting resolved in favor of the Board of Directors' proposal of April 21, 2022 to distribute a dividend for 2021 in the amount of 58,506,483.25 euros, corresponding to 0.1081 euros per share, which will be in circulation on the ex-dividend date, excluding treasury shares in portfolio at that date. The dividend will be paid on October 26, 2022 with ex-dividend date on October 24, 2022 and record date on October 25, 2022. The dividend payment notice will be published in at least one financial economic newspaper with national circulation on June 4, 2022.

Appointment of the Board of Statutory Auditors and determination of the remuneration of the Chairman of the Board of Statutory Auditors, the Board and the Statutory Auditors

The Shareholders' Meeting - on the basis of the lists filed by the Shareholder Ministry of Economy and Finance (List 1), a group of asset management companies and other institutional investors (List 2) and Inarcassa and Fondazione Enpam (List 3) - appointed the members of the Board of Statutory Auditors for the three-year period 2022-2024 in the persons of  Dario Righetti (List 2) as Chairman, Valeria Maria Scuteri  (List 1) and Giuseppe Mongiello (List 1), Standing Auditors, as well as Roberto Cassader (List 2) and Flavia Daunia Minutillo (List 1) as Alternate Auditors. The Shareholders' Meeting also resolved to confirm the fees payable to the standing members of the Board of Statutory Auditors as 40,000 euros gross per annum for the Chairman of the Board of Statutory Auditors and 25,000 euros gross per annum for each Standing Auditor, in addition to reimbursement of travel and living expenses incurred in the performance of their duties, duly documented.

Remuneration Report

Regarding the Report on Remuneration Policy and Compensation Paid prepared pursuant to Article 123-ter of Legislative Decree No. 58 of February 24, 1998 ("TUF"), the Shareholders' Meeting:

• approved by binding resolution the first section of that Report, which sets out the policy adopted by the Company on the remuneration for the year 2022 of the members of the Board of Directors and the Key Management Personnel and, without prejudice to the provisions of Article 2402 of the Civil Code, the members of the Board of Statutory Auditors

• expressed a favorable opinion, with a resolution of a non-binding nature, on the second section of said Report, containing an indication of the remuneration paid to the members of the Board of Directors and the Board of Statutory Auditors as well as to the Executives with strategic responsibilities in or relating to the year 2021

Purchase and disposition of treasury shares

At the same time, the Shareholders' Meeting resolved, at the proposal of the Board of Directors, to authorize the purchase, for a maximum duration of 18 months from the date of the resolution up to a maximum of 1,300,000 shares, as well as the disposition without time limit and even before having exhausted the purchases of all or part of the treasury shares covered by the authorization for the purchase in question as well as those already held.

Attendance at the Shareholders' Meeting

In view of the continuing uncertainty regarding the developments of the COVID-19 pandemic and in order to enable the conduct of the meeting proceedings and the exercise of Shareholders' rights in conditions of absolute safety, in accordance with the provisions of Article 106, paragraph 4 of Decree-Law No. 18 ("Cure Italy Decree"), as most recently amended by Decree-Law No. 228 of December 30, 2021, converted with amendments by Law No. 15 of February 25, 2022, the intervention of Shareholders at the Shareholders' Meeting took place exclusively through the Appointed Representative pursuant to Article 135- undecies of the TUF, to whom proxies/subdelegates were also conferred pursuant to Article 135- novies of the TUF, as an exception to Article 135-undecies, paragraph 4, of the TUF.

The meeting was well attended by shareholders, who were present with 84.016404% of the share capital.